{"id":1042722,"date":"2026-10-13T08:12:14","date_gmt":"2026-10-13T02:42:14","guid":{"rendered":"https:\/\/telecomlive.in\/web\/?p=1042722"},"modified":"2026-10-13T08:22:10","modified_gmt":"2026-10-13T02:52:10","slug":"ministry-of-science-signs-mou-with-peptris-for-collab-in-ai-based-drug-discovery-and-development","status":"publish","type":"post","link":"https:\/\/telecomlive.in\/web\/2026\/10\/13\/ministry-of-science-signs-mou-with-peptris-for-collab-in-ai-based-drug-discovery-and-development\/","title":{"rendered":"Ministry of Science signs MoU with Peptris for collab in AI-based drug discovery and development"},"content":{"rendered":"<p>The Ministry of Science&#8217;s Technology Development Board (TDB) has signed an agreement with Bengaluru-based Peptris Technologies Pvt Ltd for financial support of Rs 86 crore to accelerate the development of next-generation therapies through Artificial Intelligence (AI), it said on Monday. <\/p>\n<p>According to an official statement, the project called &#8216;VIGOR&#8211;Moving AI-Discovered Molecules from the Lab to the Clinic&#8217; has a total cost of Rs 172 crore. The aim is to advance four experimental drugs to technology readiness levels (TRLs) 4 to 6, requiring preclinical development, validation, and preparation for clinical trials. Financial support will be provided through optionally convertible debt (OCD).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Ministry of Science&#8217;s Technology Development Board (TDB) has signed an agreement with Bengaluru-based Peptris Technologies Pvt Ltd for financial support of Rs 86 crore to accelerate the development of next-generation therapies through Artificial Intelligence (AI), it said on Monday. According to an official statement, the project called &#8216;VIGOR&#8211;Moving AI-Discovered Molecules from the Lab to the Clinic&#8217; has a total cost of Rs 172 crore. The aim is to advance four experimental drugs to technology readiness levels (TRLs) 4 to 6, requiring preclinical development, validation, and preparation for clinical trials. Financial support will be provided through optionally convertible debt (OCD).<\/p>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59,4,10],"tags":[],"class_list":["post-1042722","post","type-post","status-publish","format-standard","hentry","category-it-2-the-economic-times","category-newspapers","category-the-economic-times"],"acf":[],"_links":{"self":[{"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/posts\/1042722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/comments?post=1042722"}],"version-history":[{"count":1,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/posts\/1042722\/revisions"}],"predecessor-version":[{"id":1042742,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/posts\/1042722\/revisions\/1042742"}],"wp:attachment":[{"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/media?parent=1042722"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/categories?post=1042722"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/telecomlive.in\/web\/wp-json\/wp\/v2\/tags?post=1042722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}